Why low-cost ketamine is still inaccessible to many with severe depression
By API User
A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression. Patients with treatment-resistant depression are missing out on potentially life-changing treatment with ketamine because systemic barriers in the public health system have made it unaffordable. In an article published recently in the Australian & New Zealand … Continued